SGS officially opened its new clinical pharmacology research center on the Antwerp University Hospital site on October 26, 2021, in the presence of Frankie Ng, SGS CEO.
The newly built SGS CPU, aimed at early phase research, is located next to the University Hospital of Antwerp (UZA). Its proximity to UZA reinforces scientific collaboration with a network of specialists and techniques.
This new CPU is a modern, sustainable, and innovative facility. With a capacity of 110 beds, a wide range of settings can be provided. Study participants stay in two to 8-person rooms, or in individual rooms, and have access to comfortable living and leisure areas. A high-care room allows follow-up during testing of new drugs. Two specialized quarantine units are available for controlled investigation of infection models or controlled human infection models (CHIM). In recent years, the SGS CPU has conducted the first malaria challenge studies in Belgium with its own developed H3N2 (flu) virus.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.